Table 3 Univariate and multivariable Cox analysis of BCSS and OS in training cohort.

From: Development and validation of nomograms for predicting survival in patients with de novo metastatic triple-negative breast cancer

Characteristics

Univariate analysis

Multivariable analysis

BCSS

OS

BCSS

OS

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

HR (95% CI)

P value

Year of diagnosis

2010–2013

1 [reference]

–

1 [reference]

–

    

2014–2017

0.94 (0.82–1.06)

0.274

0.93 (0.83–1.05)

0.239

    

Age (years)

18–40

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

 

41–50

1.23 (0.96–1.59)

0.108

1.19 (0.93–1.52)

0.158

1.30 (1.00–1.68)

0.046

1.26 (0.99–1.61)

–

51–60

1.12 (0.88–1.42)

0.367

1.12 (0.90–1.40)

0.319

1.15 (0.90–1.46)

0.261

1.14 (0.91–1.43)

0.064

61–70

1.27 (0.99–1.61)

0.057

1.26 (1.00–1.59)

0.046

1.18 (0.92–1.51)

0.183

1.16 (0.92–1.45)

0.246

> 70

1.65 (1.30–2.10)

< 0.001

1.68 (1.34–2.11)

< 0.001

1.54 (1.21–1.98)

< 0.001

1.52 (1.20–1.92)

0.219

Race

Black

1 [reference]

–

1 [reference]

–

    

White

0.98 (0.85–1.11)

0.711

0.96 (0.85–1.09)

0.529

    

Marital status

Married

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

Unmarried

1.38 (1.22–1.56)

< 0.001

1.41 (1.25–1.59)

< 0.001

1.17 (1.03–1.33)

0.016

1.19 (1.05–1.34)

0.005

Histology

IDC

1 [reference]

–

1 [reference]

–

    

ILC/Others

1.10 (0.95–1.28)

0.218

1.11 (0.96–1.28)

0.152

    

Tumor stage

T1

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

T2

1.19 (0.94–1.51)

0.158

1.02 (0.82–1.27)

0.832

1.29 (1.01–1.64)

0.042

1.10 (0.89–1.38)

0.377

T3

1.35 (1.05–1.74)

0.020

1.15 (0.91–1.45)

0.243

1.30 (1.00–1.69)

0.050

1.11 (0.87–1.41)

0.387

T4

1.47 (1.17–1.85)

0.001

1.31 (1.06–1.61)

0.011

1.50 (1.18–1.92)

 < 0.001

1.35 (1.08–1.64)

0.007

Node stage

N0

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

N1

1.26 (1.05–1.50)

0.011

1.21 (1.02–1.42)

0.025

1.12 (0.93–1.34)

0.222

1.09 (0.92–1.29)

0.311

N2

1.26 (1.00–1.58)

0.052

1.18 (0.95–1.47)

0.127

1.27 (1.00–1.61)

0.047

1.22 (0.97–1.52)

0.083

N3

1.29 (1.06–1.56)

0.011

1.21 (1.01–1.45)

0.044

1.33 (1.08–1.63)

0.007

1.27 (1.04–1.54)

0.017

Bone metastasis

No

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

Yes

1.30 (1.15–1.47)

< 0.001

1.30 (1.16–1.46)

< 0.001

1.27 (1.11–1.44)

< 0.001

1.27 (1.12–1.44)

< 0.001

Lung metastasis

No

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

Yes

1.21 (1.07–1.37)

0.002

1.20 (1.07–1.35)

0.002

1.08 (0.95–1.23)

0.254

1.08 (0.95–1.22)

0.258

Liver metastasis

No

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

Yes

1.61 (1.41–1.84)

< 0.001

1.59 (1.40–1.81)

< 0.001

1.64 (1.42–1.88)

< 0.001

1.63 (1.42–1.86)

< 0.001

Brain metastasis

No

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

Yes

1.89 (1.57–2.29)

< 0.001

1.72 (1.43–2.07)

< 0.001

1.91 (1.56–2.34)

< 0.001

1.72 (1.41–2.10)

< 0.001

Breast surgery

No

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

Yes

0.43 (0.40–0.52)

< 0.001

0.45 (0.40–0.51)

< 0.001

0.53 (0.46–0.61)

< 0.001

0.53 (0.47–0.61)

< 0.001

Radiotherapy

No

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

Yes

0.78 (0.68–0.89)

< 0.001

0.76 (0.67–0.86)

< 0.001

0.87 (0.75–1.01)

0.063

0.87 (0.75–0.99)

0.039

Chemotherapy

No

1 [reference]

–

1 [reference]

–

1 [reference]

–

1 [reference]

–

Yes

0.46 (0.39–0.53)

< 0.001

0.43 (0.37–0.50)

< 0.001

0.49 (0.41–0.58)

< 0.001

0.46 (0.39–0.54)

< 0.001

  1. BCSS breast cancer-specific survival, OS overall survival, HR hazard ratio, IDC infiltrating ductal carcinoma, ILC infiltrating lobular carcinoma.
Back to article page